Eli Lilly Stock News

Eli Lilly <> is trading lower after the FDA flagged its concerns on the trial data for PD-1 inhibitor Tyvyt (sintilimab) ahead of an advisory committee meeting scheduled…

Amgen Inc''s (NASDAQ: AMGN ) Q4 revenues increased 3% Y/Y to $6.84 billion , slightly missing the consensus of $6.88 billion. The increase is driven by increased revenue from the Eli Lilly And Co (NYSE: LLY ) COVID-19 manufacturing collaboration. However, its Product sales decreased 1% globally for the fourth quarter. For FY21, total revenues increased 2% to $26.0 billion. Product sales for the full year were flat versus 2020, Full story available on Benzinga.com

Shares of Amgen Inc. rose more than 3% in the extended session Monday after the drug maker reported an adjusted quarterly profit above Wall Street expectations and said sales rose in part due to COVID-19 products. Amgen said it earned $1.9 billion, or $3.36 a share, in the quarter, compared with $1.6 billion, or $2.76 a share, in the year-ago quarter. Adjusted for one-time items, Amgen earned $4.36 a share. Sales rose 3% to $6.8 billion, thanks in part to a revenue bump from its collaboration with Eli Lilly & Co. on COVID-19-related products, Amgen said. In addition, volumes grew double-digits for several products such as osteoporosis drug Prolia and high-cholesterol treatment Repatha, Amgen said. Growth in these and other products "combined with our many pipeline opportunities, position us well for long-term growth," Chief Executive Robert A. Bradway said in a statement. FactSet consensus called for earnings of $4.04 a share on sales of $6.9 billion. Amgen stock ended the regular trading day up 0.6%.

Amgen press release (AMGN): Q4 Non-GAAP EPS of $4.36 beats by $0.35.Revenue of $6.85B (+3.3% Y/Y) misses by $20M.Revenue from the Eli Lilly and Company (Lilly) COVID-19…

An FDA meeting scheduled this week to review a Chinese-developed cancer therapy is likely to be challenging for Eli Lilly, following skeptical comments published by the agency’s top cancer regulator.

We see the pushback of donanemab''s accelerated approval submission as just a speed bump.

Eli Lilly (LLY) continues to trade lower Thursday after the management indicated that the company would slow down its efforts in seeking FDA approval for its investigational therapy

Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer''s drug, saying it expects such an approval to make little difference with Medicare''s limited coverage terms.

Eli Lilly and Company (NYSE: LLY) Q4 2021 earnings call dated Feb. 03, 2022 Presentation: Operator Lladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 [] The post Eli Lilly and Company (LLY) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Jim and Jeff on all the big quarterly results from yesterday including Meta, Eli Lilly, and Honeywell.

Covid-19 drug sales reflect how the rise and fall of the variants behind successive waves of the pandemic have forced changes to treatment approaches.

Eli Lilly And Co (NYSE: LLY ) has posted Q4 sales of $7.9 billion , beating the consensus of $6.90 billion and increasing 8% Y/Y. Higher sales were driven by an 11% increase in volume, partially offset by a 3 percent decrease due to lower realized prices. Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Full story available on Benzinga.com

Eli Lilly stock dipped Thursday after it delivered a fourth-quarter beat, partially on the back of its Covid antibodies.

Eli Lilly and Co reported quarterly results on Thursday that beat analysts'' estimates as an Omicron-led surge in COVID-19 cases boosted sales of its antibody therapies, coupled with strong demand for its top-selling diabetes drug Trulicity.